QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
NASDAQ:RANI

Rani Therapeutics - RANI Stock Forecast, Price & News

$7.93
-0.13 (-1.61%)
(As of 12/9/2022 10:45 AM ET)
Add
Compare
Today's Range
$7.93
$8.09
50-Day Range
$5.81
$10.02
52-Week Range
$5.62
$27.13
Volume
202 shs
Average Volume
47,530 shs
Market Capitalization
$391.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Rani Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
177.4% Upside
$22.00 Price Target
Short Interest
Healthy
2.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Rani Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$692,741 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.26) to ($1.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

232nd out of 1,022 stocks

Pharmaceutical Preparations Industry

97th out of 499 stocks

RANI stock logo

About Rani Therapeutics (NASDAQ:RANI) Stock

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RANI Stock News Headlines

BTIG Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)
See More Headlines
Receive RANI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RANI Company Calendar

Last Earnings
11/15/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RANI
Fax
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+177.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-8,330,000.00
Pretax Margin
-3,123.76%

Debt

Sales & Book Value

Annual Sales
$2.72 million
Book Value
$2.48 per share

Miscellaneous

Free Float
23,550,000
Market Cap
$391.42 million
Optionable
Not Optionable
Beta
0.38

Key Executives

  • Mr. Mir A. Imran (Age 66)
    Exec. Chairman
    Comp: $33.33k
  • Mr. Talat Imran (Age 41)
    CEO & Director
    Comp: $1.07M
  • Mr. Svai S. Sanford (Age 52)
    Chief Financial Officer
    Comp: $675.74k
  • Dr. Mir Hashim (Age 62)
    Chief Scientific Officer
    Comp: $696.92k
  • Mr. Eric Groen
    Gen. Counsel
  • Ms. Bella Vazquez
    VP of HR













RANI Stock - Frequently Asked Questions

Should I buy or sell Rani Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rani Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RANI shares.
View RANI analyst ratings
or view top-rated stocks.

What is Rani Therapeutics' stock price forecast for 2023?

3 brokerages have issued 12-month price targets for Rani Therapeutics' shares. Their RANI share price forecasts range from $22.00 to $22.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 173.0% from the stock's current price.
View analysts price targets for RANI
or view top-rated stocks among Wall Street analysts.

How have RANI shares performed in 2022?

Rani Therapeutics' stock was trading at $16.35 at the start of the year. Since then, RANI shares have decreased by 50.7% and is now trading at $8.06.
View the best growth stocks for 2022 here
.

Are investors shorting Rani Therapeutics?

Rani Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 338,900 shares, a decrease of 19.5% from the October 31st total of 420,900 shares. Based on an average daily volume of 51,100 shares, the days-to-cover ratio is presently 6.6 days. Approximately 2.1% of the company's stock are short sold.
View Rani Therapeutics' Short Interest
.

When is Rani Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our RANI earnings forecast
.

How were Rani Therapeutics' earnings last quarter?

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02.

When did Rani Therapeutics IPO?

(RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share.

What is Rani Therapeutics' stock symbol?

Rani Therapeutics trades on the NASDAQ under the ticker symbol "RANI."

Who are Rani Therapeutics' major shareholders?

Rani Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Alphabet Inc. (1.45%), Vanguard Group Inc. (1.32%), BlackRock Inc. (0.41%), Motco (0.10%), TPB Wealth Advisors (0.10%) and Lafayette Investments Inc. (0.04%). Insiders that own company stock include Cortes Isidoro Alfonso Quiroga, Mir A Imran and South Cone Investments Limited.
View institutional ownership trends
.

How do I buy shares of Rani Therapeutics?

Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rani Therapeutics' stock price today?

One share of RANI stock can currently be purchased for approximately $8.06.

How much money does Rani Therapeutics make?

Rani Therapeutics (NASDAQ:RANI) has a market capitalization of $397.84 million and generates $2.72 million in revenue each year. The company earns $-8,330,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Rani Therapeutics have?

The company employs 114 workers across the globe.

How can I contact Rani Therapeutics?

The official website for the company is www.ranitherapeutics.com. The company can be reached via phone at 408-457-3700 or via email at ir@ranitherapeutics.com.

This page (NASDAQ:RANI) was last updated on 12/9/2022 by MarketBeat.com Staff